ARBs, alone or with a calcium channel blocker, are best-tolerated BP drugs in 700+ trials
Louis summarizes the JAMA network meta-analysis showing ARBs have fewer treatment discontinuations from side effects than even placebo. ARB plus CCB was the best-tolerated regimen, ARBs appeared in four of the top five, and CCB monotherapy was worse, suggesting ARB-based regimens may improve long-term adherence.
